Genomics and cancer treatment: new events will showcase developments

‘Most exciting cancer treatment since chemotherapy’ could save patients using DNA tests

‘New era’ of personalised cancer drugs, say doctors

4th Quality & Innovation Meeting – Pancreatic Disorders

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

A novel p53-Cdc7 link induced by genotoxic stress

Abarelix for injectable suspension

Abiraterone acetate

Ado-trastuzumab emtansine

Adrenocortical carcinoma

Afatinib

Alectinib

Alfuzosin Hydrochloride

AML and chemotherapy. A study recently co-authored by Oncologica

Anal cancer

Anaplastic astrocytoma

Aprepitant

Axitinib

Basal-cell carcinoma

Bevacizumab

Bevacizumab

Bevacizumab

Binimetinib Improves PFS in NRAS-mutant Melanoma

Bladder cancer

Bone tumour

Bortezomib

Brain Tumor

Brainstem glioma

Breast Cancer

Cabazitaxel

Cabozantinib

Cancer Conferences Participation. June 2019

Cancer treatment untested in many patients with immune problems

Capecitabine

Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint

Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment

Ceritinib

Cervical cancer

Cervical intraepithelial neoplasia

Cetuximab

Chemotherapy is no longer the only option against cancer…

Cholangiocarcinoma

Cinacalcet

Cobimetinib

Colorectal cancer

Coming ever closer – first PARP inhibitor licensed in Europe

Conjugated estrogens

Consensus on genomic classification of bladder cancer makes progress

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Crizotinib

Dabrafenib

Dad with terminal cancer given hope by ground-breaking precision oncology test

Defining cancers based on genetic ‘fingerprint’ could help personalise treatment

Degarelix for injection

Denosumab

Denosumab

Dinutuximab

DNA ‘barcode’ delivering personalised breast cancer care

Docetaxel

Doxorubicin HCl liposome injection

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Endometrial cancer

Enzalutamide

Epirubicin hydrochloride

Eribulin mesylate

Erlotinib

Esophageal cancer

Everolimus

Everolimus

Everolimus

Everolimus

Every cancer patient could have DNA tested under five-year government plan to cut deaths

Every child with cancer to have tumour DNA sequenced to find best treatment

Ewing’s sarcoma

Exemestane

Fallopian tube cancer

FDA Approves First Immunotherapy for Breast Cancer

Fentanyl buccal

Fentanyl citrate

Fentanyl sublingual spray

Fentanyl sublingual tablets

Ferumoxides

Frontline Pembrolizumab Combo Approved by FDA for NSCLC

Fulvestrant

Gallbladder cancer

Gastric cancer

Gefitinib

Gemcitabine HCL

Genetic testing of tumours could personalise cancer treatment, experts say

Germ cell tumor

Giant-cell tumor of bone

GIST

Glioblastoma

Goserelin acetate implant

Granisetron

Granisetron

Groundbreaking discovery made use skin cells to kill cancer

Human Papillomavirus Bivalent

Hypopharyngeal cancer

Ibritumomab tiuxetan

Imatinib and GISTs: Genomic Subtypes and Survival Outcomes

Imatinib mesylate

Imiquimod

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

Improving Patient Education and Access: How Can We Better Leverage Advances in Cancer Diagnostics and Treatment

Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)

Iodixanol

Ipilimumab

Irinotecan liposome injection

Ixabepilone

Kaposi’s sarcoma

Kidney cancer

Lapatinib

Laryngeal cancer

Leiomyosarcoma

Lenvatinib

Letrozole

Leuprolide acetate

Leuprolide Acetate

Levoleucovorin

Liposarcoma

Liver cancer

Lung Cancer

Lung Cancer Driver Discovery May Lead to Novel Therapy for Some Mesothelioma Patients

Malignant rhabdoid tumour

Mechlorethamine

Melanoma

Merkel-cell carcinoma

Mesothelioma

Mesothelioma shows promising response to existing immunotherapy drug

Model shows cancer’s birth and spread from single cell

Mutation-Targeted Therapy Slows Lung Cancer (NSCLC)

Mycosis fungoides

Nasopharynx cancer

Necitumumab

Neuroblastoma

New biomarker identifies uveal melanoma patients at high risk for metastasis

New Insights Into Rucaparib Activity in Ovarian Cancer

NHS should give all cancer patients personalised care

NICE says yes to Novartis’ Afinitor in kidney cancer

Nivolumab

Nivolumab

Nobel prize for medicine goes to cancer therapy

Olaparib

Olaratumab May Improve Disease Control in Certain Patients With GIST

OncoCheckpoint: Companion DX for Cdc7 inhibitors

Oncofocus a revolutionary test that can tailor the best therapy for cancer patients

Oncofocus Cancer Test and targeted therapies. The Revolution in cancer treatment has begun.

Oncofocus Cancer Test is now covered by all leading health insurers

Oncologica live on The Pat Kenny Show – IRELAND

Oncologica Ltd. to open lab in Dublin

Oncologica UK contributes to setting new guidelines for implementation of Next Generation Sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours. An expert opinion on behalf of IQN Path ASBL.

Ondansetron oral soluble film

Oropharyngeal cancer

Osimertinib

Osteosarcoma

Ovarian Cancer

Oxaliplatin

p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.

Paclitaxel

Paclitaxel protein-bound particles for injectable suspension

Palbociclib

Palonosetron

Pancreatic cancer

Pancreatic cancer found to be four separate diseases

Pancreatic neuroendocrine tumors

Panitumumab

Paraganglioma

Parathyroid carcinoma

PAT KENNY SHOW talk available as podcast

Pazopanib

Pazopanib

Pegfilgrastim

Peginterferon alfa-2b

Pembrolizumab

Pemetrexed

Pemetrexed for injection

Penile cancer

Pertuzumab

Petupitant and palonosetron

Pheochromocytoma

Pityriasis lichenoides et varioliformis acuta

Pleuropulmonary blastoma

Pralatrexate

Precision medicine can widen cancer care options, studies find

Precision medicine demonstrates benefit in late-stage cancer trial

Precision Medicine is hot topic at ASCO

Precision medicine the theme at world’s biggest cancer conference

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

Prof U. Tirelli: The best cure against cancer is a test

Prostate cancer

Quadrivalent human papillomavirus

Radium Ra 223 dichloride

Raloxifene hydrochloride

Ramucirumab

Rasburicase

Regorafenib

Regorafenib

Renal cell carcinoma

Retinoblastoma

Revolutionary test can tailor the best therapy for cancer patients

Rhabdomyosarcoma

Rolapitant

Romidepsin

Sardinia has chosen the Oncofocus test for its patients

Secretin

Sézary disease

Sipuleucel-T

Skin cancer

Soft-tissue sarcoma

Sonidegib

Sorafenib

Sorafenib

Sunitinib

Sunitinib malate

Talimogene laherparepvec

Targeted cancer care to spare thousands of patients chemotherapy

Tbo-filgrastim

Temozolomide

Temsirolimus

Testicular cancer

The cancer revolution: Personalised treatment that’s ‘six times better’ than traditional methods at beating the disease

THE ONCOFOCUS TEST

The personalisation of cancer treatments is leading to better outcomes for patients

There’s a real sense of optimism around new ways of tackling lung cancer

Thymoma

Thyroid cancer

Topotecan hydrochloride

Topotecan hydrochloride

Tositumomab

Trabectedin

Trametinib

Trastuzumab

Trifluridine and tipiracil

Triptorelin pamoate

Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

Two combination therapies shrink melanoma brain metastases in more than half of patients

UK chief medical officer calls for gene testing revolution within five years. But the revolution is actually already here.

Uveal melanoma

Vaginal cancer

Vandetanib

Vemurafenib

Vismodegib

Vulvar cancer

Wilms’ tumour

World Cancer Day 2017

Ziv-aflibercept

Zoledronic acid

Zoledronic acid